The investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine ...
Dec 8, 2021
0
1
High-dose radiation therapy can be used to lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted the growth or spread of metastases, according to a new study. Findings ...
Oct 25, 2021
0
2
Combination of the KRAS inhibitor sotorasib (Lumakras) with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating non-small cell lung cancer (NSCLC) patients with mutated KRAS whose disease had progressed ...
Oct 7, 2021
0
0
The development of new research guidelines for interventional oncology that standardize treatment outcomes and the reporting of data represents a major step forward for an increasingly important medical subspecialty, according ...
Sep 28, 2021
0
2
During the virtual 2021 Annual Congress of the European Society for Medical Oncology (ESMO), 16-21 September, research (co) led by VHIO investigators revealed promising advances in the treatment of metastatic breast cancer. ...
Sep 20, 2021
0
3
Treatment with atezolizumab plus carboplatin and pemetrexed was safe and yielded promising brain progression-free survival in patients with nonsquamous non-small cell lung cancer with untreated and asymptomatic brain metastases. ...
Sep 10, 2021
0
2
Patients with metastatic non-small cell lung cancer (mNSCLC) who received a combined regimen of durvalumab, tremelimumab, and chemotherapy experienced a statistically significant improvement in progression-free survival and ...
Sep 9, 2021
0
0
Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. ...
Jan 31, 2021
0
3
Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung ...
Jan 30, 2021
0
2
In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer (NSCLC) and who harbor KRAS p.G12C mutations, validating ...
Jan 28, 2021
0
4
